Advertisement
NUVB vs SVRA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVB is a StrongBuy and SVRA is a Hold.
NUVB's RSI Indicator ascends from oversold territory
The RSI Oscillator for NUVB moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 30 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 64 cases where NUVB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for NUVB just turned positive on October 21, 2026. Looking at past instances where NUVB's MACD turned positive, the stock continued to rise in 49 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUVB advanced for three days, in 205 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NUVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for NUVB crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for NUVB entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.708) is normal, around the industry mean (2.988). P/E Ratio (-11.023) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (11.765) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. NUVB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SVRA in -6.51% downward trend, declining for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SVRA declined for three days, in 199 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SVRA as a result. In 79 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for SVRA turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 30 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
The Aroon Indicator for SVRA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SVRA's RSI Indicator exited the oversold zone, 20 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where SVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where SVRA advanced for three days, in 191 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. SVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.679) is normal, around the industry mean (2.988). P/E Ratio (-8.052) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NUVB | SVRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 49 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 61 | |
P/E GROWTH RATING 1..100 | 19 | 25 | |
SEASONALITY SCORE 1..100 | 16 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NUVB's Valuation (24) in the null industry is somewhat better than the same rating for SVRA (69) in the Biotechnology industry. This means that NUVB’s stock grew somewhat faster than SVRA’s over the last 12 months.
SVRA's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for NUVB (100) in the null industry. This means that SVRA’s stock grew somewhat faster than NUVB’s over the last 12 months.
NUVB's SMR Rating (98) in the null industry is in the same range as SVRA (99) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.
SVRA's Price Growth Rating (61) in the Biotechnology industry is in the same range as NUVB (63) in the null industry. This means that SVRA’s stock grew similarly to NUVB’s over the last 12 months.
NUVB's P/E Growth Rating (19) in the null industry is in the same range as SVRA (25) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.
| NUVB | SVRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 77% |
| Momentum ODDS (%) | N/A | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 86% | 7 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NUVB’s FA Score shows that 2 FA rating(s) are green while SVRA’s FA Score has 1 green FA rating(s).
- NUVB’s FA Score: 2 green, 3 red.
- SVRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NUVB’s TA Score shows that 5 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).
- NUVB’s TA Score: 5 bullish, 3 bearish.
- SVRA’s TA Score: 4 bullish, 4 bearish.
Price Growth
NUVB (@Biotechnology) experienced а +3.63% price change this week, while SVRA (@Biotechnology) price change was -1.89% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
NUVB is expected to report earnings on Nov 02, 2026.
SVRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NUVB and
Correlation & Price change
A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with SVRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To NUVB | 1D Price Change % | ||
|---|---|---|---|---|
| NUVB | 100% | +1.68% | ||
| SVRA - NUVB | 45% Loosely correlated | -1.89% | ||
| FDMT - NUVB | 41% Loosely correlated | -3.66% | ||
| VCYT - NUVB | 40% Loosely correlated | +3.19% | ||
| ANNX - NUVB | 39% Loosely correlated | +0.78% | ||
| RAPP - NUVB | 38% Loosely correlated | -14.67% | ||
More | ||||
SVRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with FDMT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To SVRA | 1D Price Change % | ||
|---|---|---|---|---|
| SVRA | 100% | -1.89% | ||
| FDMT - SVRA | 48% Loosely correlated | -3.66% | ||
| MGTX - SVRA | 48% Loosely correlated | -1.10% | ||
| NUVB - SVRA | 45% Loosely correlated | +1.68% | ||
| PHVS - SVRA | 45% Loosely correlated | -0.78% | ||
| KYTX - SVRA | 44% Loosely correlated | -3.31% | ||
More | ||||